Jasper Therapeutics Inc. (NASDAQ: JSPR) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT JASPER THERAPEUTICS INC.

Jasper Therapeutics Inc. (NASDAQ: JSPR)
Listen to this Section


$6.80
+0.4780 ( +6.55% ) 250.8K

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Market Data


Open $6.80
Previous Close $6.32
Volume 250.8K
Market Cap $94.81M
Day Range $6.21 - $6.80
52 Week Range $5.25 - $31.01
Shares Outstanding 15.00M
Change % +6.55%
Net Change ▲ 0.4780
Insider Ownership 0.00%
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology: Biological Products (No Diagnostic Substances)
IPO Year 2021
Country United States
Under Writer IPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -527,322.00

Date Type Amount Purchased Purchaser
2024-06-20 Sale -15000.00 Lucas Svetlana
2024-06-12 Sale -10000.00 MARTELL RON
2024-06-12 Sale -900.00 Mahal Jeetinder Singh
2024-06-10 Sale -7500.00 Kapoor Vishal
2024-06-10 Sale -7500.00 WIGGANS THOMAS G
2024-06-10 Sale -7500.00 Brun Scott C.
2024-06-10 Sale -7500.00 EMSTER KURT VON
2024-06-10 Sale -400.00 Tucker Edwin Jonathan
2024-06-10 Sale -7500.00 French Anna Louise
2024-06-10 Sale -7500.00 Nolet Chris

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
s-8 Registration statements 6 Jun 07, 2024
s-8 Registration statements 12 Jun 07, 2024
s-8 Registration statements 6 Jun 07, 2024
10-q Quarterly Reports 74 May 14, 2024
defa14a Other 1 May 03, 2024
ars Annual reports 1 Apr 22, 2024
def Proxies and info statements 3 Apr 22, 2024
defa14a Other 3 Apr 22, 2024
sc Insider transactions 1 Mar 27, 2024
4 Insider transactions 1 Mar 12, 2024

Latest News


× Before browsing our site, please accept our cookies policy